Summary.-The value of the leucocyte adherence inhibition (LAI) test in the diagnosis of hepatocellular carcinoma (HCC) was investigated in 36 patients with this tumour. The sensitivity and specificity of the tube LAI test was assessed in 21 patients with HCC, 15 apparently healthy individuals, 9 patients with various forms of benign liver disease and 5 patients with non-hepatic neoplasms. In only 42% of the HCC patients tested was leucocyte adherence to glass reduced to a greater extent than in the healthy controls and in the patients with non-hepatic neoplasms, and the differences were not statistically significant. Moreover, positive results were obtained in 6/9 patients with benign hepatic disease. A further 15 patients were tested against extracts of HCC tissue using the haemacytometer LAI method. Of these, 53o% gave positive results. In all, only 17/36 patients (47°,) gave positive LAI responses. The test is thus of limited value in the diagnosis of HCC. The high false-negative result rate may be due either to abrogation of the immune response in HCC patients with large tumour burdens or to antigenic heterogeneity in HCC.
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MOST MALIGNANT TUMIOURS in man and experimental animals possess characteristic antigens which permit differential imm-unoreactivity to be demonstrated (Hellstrom et al., 1971) . A number of in vitro methods have been used to detect such reactivity, including cytotoxicity testing (Jagarlamoody et al., 1971) , leucocyte migration inhibition (Bull et al., 1973) , and lymphocyte transformation (Vainky et al., 1971) . More recently the leucocyte adherence inhibition (LAI) test has been developed as a simple and rapid technique for detecting cell-mediated immune response to soluble tumour-associated antigens (Halliday & Miller, 1972; Halliday et al., 1974; Grosser & Thomson, 1975) . This test has been used in assessing reactivity to a wide variety of tumours (Tataryn et al., 1978; Maluish & Halliday, 1974) including hepatocellular carcinoma (HCC) . In the latter study, positive LAI tests were found in a few patients with HCC. However, this observation has not been confirmed, and the purpose of the present study was to evaluate the diagnostic usefulness of the LAI test in a larger number of patients.
SUBJECTS STUDIED AND METHODS
Subjects. Twenty-one patients with histologically proven HCC were investigated using a modification of the tube LAI test. An additional 16 patients were studied with the haemacytometer LAI method. The age of the patients ranged from 22 to 63 years, with a mean of 45-5 years. Each patient was studied before treatment wNas begun. All but one of the patients in whom follow-up information was obtained had died within 3 months of diagnosis. The control group consisted of 15 apparently healthy age-matched subjects, 9 patients with benign hepatic disease (6 with acute viral hepatitis, of whom 4 were hepatReprint requests to: Professor AM. inter-face -were aspirated. diluted 1: 5 with rninimal essential medium (MEM-Burroughs Wellcome), and centrifuged at 400 g for 10 min. The cells -were then -washed x 3, after w1hich they were resuspended to a concentration of 4 x 1(7 cells/rnl medium (Rutherford et al., 1977 (Howell, 1979) . In the haemacytometer system T-lymphocyte reactivity and production of a lymphokine, leucocyte adherence inhibition factor (LAIF), may be responsible for reduced leucocyte adherence. Proteases released by tumours are thought to inactivate LAIF (Halliday, 1979) . These proteases may themselves be inactivated by factors present in serum. The addition of serum to the test system used in the detection of LAIF is therefore necessary. In the tube method, the macrophage appears to be the reactive cell, and reduced macrophage adherence to glass may be the result of binding of cytophilic antitumour antibody to macrophage Fe receptors. In this method serum is not used, since the addition of serum causes nonspecific inhibition of leucocyte adherence (Thomson & Crosser, 1979) .
In the present study we first used the tube method. However, in only 42 o of the patients was there greater LAI than found in healthy subjects, and the high false-negative rate in our hands severely The absence of tube LAI reactivity in the majority of our patients with HCC may reflect abrogation of specific tumnour immunity as a result of blocking of effector cells by the systemic release of excess soluble tumour antigen by a large tumour mass. Certainly, tumour antigenic determinants may absorb cytophilic antitumour antibody (Thomson & Crosser, 1979) . Leucocyte reactivity in experimental animals with large tumour masses has been shown to be diminished (Leveson et al., 1977) and Grosser& Thomson (1975) demonstrated a similar phenomenion in patients with advanced breast cancer. Recently, studies of LAI in pancreatic (Tataryn et al., 1978) , breast (Lopez et al., 1977) and colorectal carcinomas (Shani et al., 1978) may obviate these shortcomings.
LAI assays may thus be potentially useful research and diagnostic tools in the investigation of tumour immunity, but in this study, using crude membrane extracts, they did not satisfy the need for a rapid im munodiagnostic test in patients with 11CC.
This work wN-as supported in part by a granit from thle Nation-al Cancer Association of South Africa.
